TBG Diagnostics

Progen’s vision is two-fold: to improve cancer patients’ lives by providing them with improved oncology solutions; and to create long-term shareholder value through the discovery and development of novel cancer therapeutics

1 past transactions

CellGate

Acquisition in 2008
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.